ACET Adicet Bio Inc

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications Presenting Author: Yvan Chanthery, Ph.D. Date & Time: June 14, 2024 at 18:00 CEST

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

Adicet Bio., Inc. Investor and Media Contacts

Anne Bowdidge abowdidge@adicetbio.com

Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com

Adicet Bio (NASDAQ:ACET)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

Adicet Bio (NASDAQ:ACET)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024